



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
		Application Number	09/981,685		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Filing Date	10/17/2001		
		First Named Inventor	Graham et al.		
		Group Art Unit	1636		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	ADVEC101A-C5A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
W		ANTON, M., and F.I. GRAHAM, 1995, Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression, J. Virol. 69: 4600-4606.
W		ARAKI, K., J. ARAKI, J.I. MIYAZAKI, and P. VASSALI, 1995, Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc. Nat'l. Acad. Sci. USA 92: 160-164.
W		BETT, A.J., I. PREVEC, and F.L. GRAHAM, 1993, Packaging capacity and stability of human adenovirus type 5 vectors, J. Virol. 67, 5911-5921.
W		BETT, A.J., W. HADDARA, L. PREVEC, and F.L. GRAHAM, 1994, An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early region 1 and 3, Proc. Nat'l. Acad. Sci. USA 91, 8802-8806.
W		CRYSTAL, R.G., N.G. MCELVANCY, M.A. ROSENFELD, C.S. CHU, A. MASTRANGELI, J.G. HAY, S.L. BRODY, H.A. JAFFE, N.T. EISSA, and C. DANIEL, 1994 Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis, Nature Genetics 8: 42-51.
W		DISANTO, J.P., W. MUELLER, D. GUY-GRAND, A. FISCHER, and K. RAJEWSKY, 1995, Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor chain, Proc. Nat'l. Acad. Sci. USA 92: 377-381.
W		GAGE, P.J., B. SAUER, M. LEVIN and J.C. GLORIOSO, 1992, A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J. Virol. 66: 5509-5515.
W		GRAHAM, F.L. and L. PREVEC, 1991, Manipulation of adenovirus vectors. In Murray E.J. (ed.), Methods in Molecular Biology, The Humana Press Inc. Clifton NJ Vol. 7 (Gene Transfer and Expression Protocols): 109-128.
W		GRAHAM, F.L. and L. PREVEC, 1992, Adenovirus-based expression vectors and recombinant vaccines in: Vaccines: New Approaches in Immunological Problems., ed. Ellis R.W. Butterworth-Heinemann, Boston, MA: 363-390.
W		GRAHAM, F.L., J. SMILEY, W.C. RUSSEL, and R. NAIRN. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen Virol. 36: 59-72.
W		GU, J.H., D. MARTH, P.C. ORBAN, H. MOSSMANN, and K. RAJEWSKY, 1994, Deletion of a DNA polymerase B gene segment in T cells using cell type-specific gene targeting. Science 265: 103-106.
W		KILBY, N.J., M.R. SNAITH, and J.A.H. MURRAY, 1993, Site-specific recombinases; tools for genome engineering. Trends Genet. 9: 413-421.

Examiner Signature	<i>[Signature]</i>	Date Considered	3/5/04
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



PTO/SB/088 (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
		Application Number	09/981,685		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Filing Date	10/17/2001		
		First Named Inventor	Graham et al.		
		Group Art Unit	1636		
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	ADVEC101A-C5A

RECEIVED

JUN 25 2003

GROUP 1700

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
W		METZGER, D., J. CLIFFORD, H. CHIBA and P. CHAMBON. 1995. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre protein. Proc. Nat'l. Acad. Sci. USA 92: 6991-6995.
W		PICHEL, J.G., LAKSO, and WESTPHAL. 1993. Timing of SV40 oncogene activation by site-specific recombination determines subsequent tumor progression during murine lens development. Oncogene 8: 3333-3342.
W		SAUER, B.. 1994. Site-specific recombination: developments and application. Cur. Opin. Biotech. 5: 521-527.
W		SAUER, B. and N. HENDERSON. 1989. Cre-stimulated recombination of loxP-containing DNA sequences placed into the mammalian genome. Nucl. Acids Res. 17: 147-161.
W		SAUER, B., and N. HENDERSON. 1990. Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre-recombinase. The New Biologist 2: 441-449.
W		SAUER, B., M. WHEALY, A. ROBBINS and L. ENQUIST. 1987. Site-specific insertion of DNA into a pseudorabies virus vector. Proc. Nat'l. Acad. Sci. USA 84: 9108-9112.
W		SMITH A.J., M.A. DESOUSA, B. KWABI-ADDU, A. HEPPELL-PARTON, H. IMPEY, and P. RABBITS. 1995. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nature Genetics 9: 376-385.
W		RABBITS, 1995. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nature Genetics 9: 376-385.
W		STERNBERG, N., B. SAUER, R. HOESS, and K. ABREMSKI. 1986. Bacteriophage P1 cre gene and its regulatory region; Evidence for multiple promoters and for regulation by DNA methylation. J. Mol. Biol. 187: 197-212.
W		VAN DEURSEN, J. M. FORNEROD, B. VAN REES, and G. GROSVELD. 1995. Cre-mediated site specific translocation between non-homologous mouse chromosomes. Proc. Nat'l. Acad. Sci. USA 92: 7376-7380.
W		MITTAL, S.K., MCDERMOTT, M.R., JOHNSON, D.C. PREVEC, L., and F.L. GRAHAM. 1993. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Research, 28: 67-90.
W		HANKE, T., FRANK L. GRAHAM, KENNETH L. ROSENTHAL and DAVID C. JOHNSON. 1991. Identification of an immunodominant cytotoxic t-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. 1991. J. of Virology, 65: 1177-1186.

RECEIVED

JUN 26 2003


TECH CENTER 1600/2900

Examiner Signature	<i>[Signature]</i>	Date Considered	3/5/04
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Control Number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	09/981,685
				Filing Date	10/17/2001
				First Named Inventor	Graham et al.
				Group Art Unit	1836
				Examiner Name	
				Attorney Docket Number	ADVEC10IA-C5A
Sheet	4	of	4		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
W		GRAHAM, F.L., 1987. Growth of 293 cells in suspension culture. J. Gen. Virol. 68: 937-940.
W		QUANTIN, B., LESLIE D. PERICAUDET, SHAHRAGIM TAJBAKSH and JEAN-LOUIS MANDEL. 1992 Adenovirus as an expression vector in muscle cells in vivo. Proc. Nat'l. Acad. Sci. 89: 2581-2584.
W		BETT, A.J., WAEL HADDARA, LUDVIK PREVEC and FRANK L. GRAHAM. 1994. Proc. Nat'l. Acad. Sci. 91: 8802-8806.
W		ROSENFELD, M.A. et al., 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium, Cell. 68: 143-155.
W		W.J. MCGRORY, D.S. BAULISTA and F.L. GRAHAM. 1988. A simple technique for the rescue of ear region 1 mutations into infectious human adenovirus type 5, Virology 163: 614-617.
W		ORKIN ET AL., Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Distributed by the National Institutes of Health, Bethesda, MD, Dec. 7, 1995.
W		RUSS, ANDREAS P., ET AL. 1996. Self-deleting Retrovirus Vectors for Gene Therapy. J. of Virology, pp. 4927-4932.
W		WANG, P., ANTON, F.L. GRAHAM, and S. BACCHETTI. High Frequency recombination between loxP sites in human chromosomes mediated by an adenovirus vector expressing Cre recombinase. Somatic Cell and Molecular Genetics. Vol. 21. 1995, pp 429-441.
W		SAUER, BRIAN and NANCY HENDERSON. 1988. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Nat'l. Acad. Sci. USA 85: 5166-5170.
W		GUDRUN SCHIEDNER, et al., 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genetics 18: 180-183.
W		MANAL A. MORSY, et al., 1998. An Adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Nat'l. Acad. Sci. USA 95: 7866-7871.
W		PARKS, ET AL., 1996. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Nat'l. Acad. Sci. USA 93: 13565-13570.
W		STEPHEN HARDY, ET AL., 1997. Construction of Adenovirus Vector through Cre-lox Recombination. Jour. Virol. 71:3 1842-1849.

Examiner Signature	<i>W. J. Hardy</i>	Date Considered	3/5/04
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

RECEIVED

JUN 25 2003

GROUP 1700

RECEIVED

JUN 26 2003

TECH CENTER 1000/2900



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/981,682
				Filing Date	10/17/2000
				First Named Inventor	Graham et al.
				Art Unit	1836
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ADVEC101A-C5A
Sheet	1	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
<i>mn</i>		US-4,510,245	04-09-1985	Cousens et al.	
<i>mn</i>		US-4,787,368	01-10-1989	Carter et al.	
<i>mn</i>		US-4,920,209	04-24-1990	Davis et al.	
<i>mn</i>		US-4,920,211	04-24-1990	Tibetis et al.	
<i>mn</i>		US-5,434,068	07-1995	Bebbee et al.	
<i>mn</i>		US-5,670,488	09-23-97	Gregory et al.	
<i>mn</i>		US-5,817,492	10-1998	Saito et al.	
<i>mn</i>		US-5,882,877	03-16-1999	Gregory et al.	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
<i>mn</i>		EP 0300422		01/1989		
<i>mn</i>		WO 93/19092		09/1993		
<i>mn</i>		WO 93/06223		04-01-1993		
<i>mn</i>		WO 93/19191		09/1993		
<i>mn</i>		WO 94/08026		04-14-1994	Kahn et al.	
<i>mn</i>		WO 94/12649		06-09-1994	Gregory et al.	
<i>mn</i>		WO 95/27071		10-1995	University of Texas	
<i>mn</i>		WO 96/13597		04-09-1996	Wilson et al.	
<i>mn</i>		WO 97/25446		07-1997	Kaleko	
<i>mn</i>		WO 97/32481		09-12-1997	Hardy	

Examiner Signature	<i>My T. Vogel</i>	Date Considered	3/5/04
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.